Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
September 22, 2009 09:03 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - September 22, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL), a
specialist oncology company focusing on the clinical development of novel
anti-cancer therapeutics, today...
HemoBioTech Gains Congressional Recognition of Its Blood Substitute Technology
August 17, 2009 08:38 ET
|
HemoBiotech
DALLAS, TX--(Marketwire - August 17, 2009) - HemoBioTech, Inc. (OTCBB: HMBT) has been working
with a coalition of small biotechnology firms to implement legislation that
will strengthen the Federal...
WHITECOAT Strategies and Comprendia Sign Strategic Partnership Agreement to Better Target Key Opinion Leaders, Patients, and Advocates
August 12, 2009 08:00 ET
|
WHITECOAT Strategies
WASHINGTON, DC and SAN DIEGO, CA--(Marketwire - August 12, 2009) - WHITECOAT Strategies, a
public relations firm specializing in the use of new media and online video
for clients with innovative...
Biota Holdings Announces Successful Phase III Asian Clinical Trials of Its Second Generation Flu Treatment
August 10, 2009 05:00 ET
|
Biota
WASHINGTON, DC--(Marketwire - August 10, 2009) - Biota Holdings Limited (ASX: BTA) today
announced successful results from the Asian Phase III clinical trials of
CS-8958, its second generation...
Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
August 05, 2009 08:05 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have
concluded a license agreement for...
Novogen Director Retires
July 30, 2009 08:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - July 30, 2009) - The Board of Novogen Limited (ASX: NRT)
(NASDAQ: NVGN) has received and accepted the resignation of Mr. Peter B.
Simpson as a Director of the...
Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
July 07, 2009 08:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - July 7, 2009) - Researchers at the
Malaghan Institute of Medical Research in Wellington, New Zealand have
found that abnormally proliferating human...
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
June 17, 2009 08:30 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - June 17, 2009) - The Independent Data Monitoring Committee
(IDMC) created to oversee the conduct of the Phase III OVArian TUmor
REsponse (OVATURE) Trial, which convened...
HemoBioTech to Present "Need for Blood Substitute to Prevent HIV Transmission" at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
June 02, 2009 10:00 ET
|
HemoBiotech
DALLAS, TX--(Marketwire - June 2, 2009) - Representatives from HemoBioTech, Inc. (OTCBB: HMBT) will present "Developing blood substitutes for the prevention of HIV
transmission," at the 5th...
Published Studies Back Use of Latex Gloves in Swine Flu Kits
May 12, 2009 08:00 ET
|
MREPC
WASHINGTON, DC--(Marketwire - May 12, 2009) - Amidst measures being taken to address the
swine flu (H1N1 virus) outbreak, Operation USA and other groups are
distributing precautionary kits that...